Four-Day Calcipotriene and Fluorouracil: What the Study Compared

Four days of applications can still involve a longer period of inflamed skin. If your dermatologist suggests calcipotriene plus fluorouracil for actinic keratoses, ask about both calendars: when to apply the medicine and what to expect after the final dose.¹

Actinic keratoses, or AKs, are precancerous growths associated with ultraviolet damage. A dermatologist should examine the skin before choosing treatment. Calcipotriene is also called calcipotriol; the older study uses that name.²³

The control group also used fluorouracil for four days

A 2017 trial² analyzed 130 participants aged 50 or older. Both groups applied pharmacy-prepared mixtures twice daily for four days: calcipotriol plus fluorouracil, or petroleum jelly plus fluorouracil.²

At week 8, average facial AK counts fell 87.8% with the combination versus 26.3% with control. Complete facial clearance occurred in 27% versus 0%. The 87.8% figure meant fewer lesions, not that 87.8% of people cleared.²

The control stopped after four days. Fluorouracil-alone guidance describes 2 to 4 weeks, a course this trial did not compare.²³

The last application did not end the skin reaction

Delayed redness affected 91% of combination recipients, often peaking around days 10 to 11. Reactions resolved around the two-week assessment, but individual healing may differ.²

The UK Primary Care Dermatology Society¹ advises people to stop and contact a healthcare professional if the reaction becomes very severe, painful or intolerable. Arrange that contact route before starting, including whom to reach outside clinic hours. Do not extend treatment because the skin has not yet reacted, or restart it because roughness remains, without checking the prescription.¹

The cancer follow-up was a smaller cohort

A 2019 follow-up examined later skin-cancer outcomes among participants from the earlier trial. It was not a new, larger randomized trial. People lost to follow-up or taking immunosuppressive medicines were excluded.⁴

Within three years, squamous cell carcinoma developed on treated face or scalp skin in 2 of 30 combination recipients (7%) versus 11 of 40 controls (28%). The reported hazard ratio was 0.215, with a wide 95% confidence interval of 0.048 to 0.972.⁴

Those findings suggest a possible preventive benefit, but the small number of cancers and exclusions limit confidence. The longer time-to-event analysis extending beyond 1,500 days did not reach statistical significance. The study also found no significant reduction in basal cell carcinoma on the treated face or scalp. It does not establish protection against every skin cancer or at every body site.⁴

Four days is not a universal prescription

A 2026 consensus paper⁵ from nine dermatologists and dermatologic surgeons proposed AK schedules of 4 to 5 days for the face or neck, and 7 to 10 days for the scalp, trunk or extremities. These were expert recommendations informed by the literature and clinician experience, rather than a trial proving those schedules superior. The authors acknowledged a small panel and limited underlying studies.⁵

In the US, calcipotriene ointment’s labeled indication is plaque psoriasis. Its use in this AK combination is off-label. The label also advises against facial use. Ask the prescriber to explain the combination plan, any differences from the leaflet and how the formulation will be supplied.⁶

Before collecting the prescription, get written answers to these questions:

• Which diagnosed area should I treat, and which nearby areas should I avoid?
• What are my exact first and last application dates?
• What washing, moisturizer and sun-protection instructions apply while the area is inflamed?
• Which symptoms mean stop, whom should I contact, and when is the review appointment?

Mention pregnancy, pregnancy plans or breastfeeding before treatment. The combination-treatment leaflet advises against use during pregnancy or breastfeeding.¹

Continue skin checks and dermatology appointments after treatment. Ongoing protection includes shade, protective clothing and broad-spectrum, water-resistant SPF 30 or higher sunscreen. Clearing existing AKs does not end the follow-up plan.⁷

Skin, Head to Toe, Chapter 3’s “What to Say at the Appointment,” suggests bringing your product history and asking the clinician to explain unfamiliar terms. Bring the actual prescription instructions too, so the application dates and recovery plan can be checked together.